- Home
- SDHC vs MDXG Comparison
SDHC vs MDXG Comparison
Compare SDHC & MDXG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SDHC
- MDXG
- Stock Information
- Founded
- SDHC 2008
- MDXG 2006
- Country
- SDHC United States
- MDXG United States
- Employees
- SDHC N/A
- MDXG N/A
- Industry
- SDHC
- MDXG Biotechnology: Pharmaceutical Preparations
- Sector
- SDHC
- MDXG Health Care
- Exchange
- SDHC Nasdaq
- MDXG Nasdaq
- Market Cap
- SDHC 933.4M
- MDXG 1.0B
- IPO Year
- SDHC 2024
- MDXG N/A
- Fundamental
- Price
- SDHC $18.78
- MDXG $6.43
- Analyst Decision
- SDHC Hold
- MDXG Strong Buy
- Analyst Count
- SDHC 4
- MDXG 2
- Target Price
- SDHC $23.63
- MDXG $12.50
- AVG Volume (30 Days)
- SDHC 53.9K
- MDXG 829.9K
- Earning Date
- SDHC 05-14-2025
- MDXG 04-30-2025
- Dividend Yield
- SDHC N/A
- MDXG N/A
- EPS Growth
- SDHC N/A
- MDXG N/A
- EPS
- SDHC 0.24
- MDXG 0.27
- Revenue
- SDHC $1,010,976,000.00
- MDXG $352,375,000.00
- Revenue This Year
- SDHC $6.51
- MDXG $9.44
- Revenue Next Year
- SDHC $11.93
- MDXG $11.54
- P/E Ratio
- SDHC $79.78
- MDXG $23.83
- Revenue Growth
- SDHC 28.67
- MDXG 5.34
- 52 Week Low
- SDHC $16.28
- MDXG $5.47
- 52 Week High
- SDHC $39.50
- MDXG $10.14
- Technical
- Relative Strength Index (RSI)
- SDHC 50.39
- MDXG 38.95
- Support Level
- SDHC $16.28
- MDXG $6.46
- Resistance Level
- SDHC $18.45
- MDXG $6.90
- Average True Range (ATR)
- SDHC 1.18
- MDXG 0.23
- MACD
- SDHC 0.05
- MDXG -0.05
- Stochastic Oscillator
- SDHC 52.14
- MDXG 1.02
About SDHC Smith Douglas Homes Corp.
Smith Douglas Homes Corp is a company engaged in the design, construction, and sale of single-family homes in some of the highest growth and desirable markets in the Southeastern United States. It is organized into eight geographical divisions which comprise two reportable segments. Its Southeast segment consists of Atlanta, Central Georgia, Charlotte, Greenville, and Raleigh divisions. Its Central segment consists of Alabama, Houston, and Nashville divisions.
About MDXG MiMedx Group Inc
MiMedx Group Inc develops and markets regenerative biomaterial products and bioimplants made from the human amniotic membrane, birth tissues, and human skin & bone. Its products are primarily targeted towards the wound-care, burn, surgical, sports medicine, and orthopedics markets. MiMedx's key products are allografts processed from amniotic tissue, which include EpiFix for external use and AmnioFix for internal use. AmnioCord, AmnioFill, EpiBurn, and EpiCord are some of its other products. Also, it sells allografts for ophthalmic surgery and dental applications through licenses to third parties.